Cogent Biosciences, Inc. (COGT)

NASDAQ: COGT · IEX Real-Time Price · USD
11.10
-0.13 (-1.16%)
At close: Dec 9, 2022 4:00 PM
11.22
+0.12 (1.08%)
After-hours: Dec 9, 2022 4:45 PM EST
-1.16%
Market Cap 784.90M
Revenue (ttm) n/a
Net Income (ttm) -125.54M
Shares Out 69.58M
EPS (ttm) -2.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 619,319
Open 11.2
Previous Close 11.23
Day's Range 11 - 11.47
52-Week Range 3.79 - 18.07
Beta -0.71
Analysts Buy
Price Target 21.59 (+94.5%)
Earnings Date Nov 16, 2022

About COGT

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly... [Read more]

Industry Biotechnology
IPO Date Mar 29, 2018
Employees 121
Stock Exchange NASDAQ
Ticker Symbol COGT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for COGT stock is "Buy." The 12-month stock price forecast is 21.59, which is an increase of 94.50% from the latest price.

Price Target
$21.59
(94.50% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Tri...

WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined d...

4 days ago - GlobeNewsWire

Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development

WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined d...

1 week ago - GlobeNewsWire

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results

Phase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal tumor (GIST) patients; initial safety and pharmacokinetic data from lead-in p...

3 weeks ago - GlobeNewsWire

Cogent Biosciences Announces Participation at Upcoming Investor Conferences

WALTHAM, Mass. and BOULDER, Colo., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined di...

1 month ago - GlobeNewsWire

Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting

Company to Host Virtual Investor Event on Monday, December 12 Company to Host Virtual Investor Event on Monday, December 12

1 month ago - GlobeNewsWire

Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined di...

1 month ago - GlobeNewsWire

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results

On-track to present additional data from Phase 2 APEX trial by the end of 2022

4 months ago - GlobeNewsWire

Cogent Biosciences, Inc. (COGT) Is a Great Choice for "Trend" Investors, Here's Why

Cogent Biosciences, Inc. (COGT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made ...

4 months ago - Zacks Investment Research

Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 66.1% in Cogent Biosciences, Inc. (COGT). While the effectiveness of this highly sought-after metric is questiona...

4 months ago - Zacks Investment Research

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exer...

CAMBRIDGE, Mass. and BOULDER, Colo., June 16, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

5 months ago - GlobeNewsWire

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants

CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

5 months ago - GlobeNewsWire

Cogent (COGT) Surges on Robust Data from Mastocytosis Study

Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.

5 months ago - Zacks Investment Research

Cogent Biosciences Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

5 months ago - GlobeNewsWire

Cogent Biosciences (COGT) Stock Soars 90% on Positive Clinical Data

Today, investors in Cogent Biosciences and COGT stock have some promising clinical trial results to look at, as this stock soars. The post Cogent Biosciences (COGT) Stock Soars 90% on Positive Clinical ...

5 months ago - InvestorPlace

Why Shares Of Cogent Biosciences Are Trading Higher

Cogent Biosciences, Inc. (NASDAQ: COGT) shares are trading higher after the company reported initial data from its ongoing Phase 2 APEX clinical trial. All patients treated with bezuclastinib achieved g...

5 months ago - Benzinga

Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib ...

All patients treated with bezuclastinib achieved ≥ 50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment

5 months ago - GlobeNewsWire

Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET

– Event to review initial clinical data from APEX, a Phase 2 trial with bezuclastinib in Advanced Systemic Mastocytosis presented at European Hematology Association (EHA) Congress – Event to review init...

6 months ago - GlobeNewsWire

Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress

Poster to highlight initial data from on-going Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) Poster to highlight initial data from on-going Phase 2 ...

6 months ago - GlobeNewsWire

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results

Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress

6 months ago - GlobeNewsWire

Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium

CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined d...

7 months ago - GlobeNewsWire

Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&...

New bezuclastinib nonclinical data demonstrate superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors

7 months ago - GlobeNewsWire

Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results

APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients

8 months ago - GlobeNewsWire

Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022

CAMBRIDGE, Mass. and BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

9 months ago - GlobeNewsWire

Cogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

10 months ago - GlobeNewsWire

Cogent Biosciences Provides 2022 Corporate Guidance

CAMBRIDGE, Mass. and BOULDER, Colo.

11 months ago - PRNewsWire